Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation

Summary

350 patients with early leukemias were assigned to receive peripheral blood or bone marrow transplantation; the occurrence of acute and chronic graft versus host disease, survival, transplantation-related mortality, and relapse rates were compared.

Conditions

• Acute Leukemia
• Chronic Myelogenous Leukemia
• Myelodysplastic Syndrome

Interventions

PROCEDURE

Bone marrow transplantation

Patients received bone marrow transplantation

PROCEDURE

Peripheral blood stem cell transplantation

Patients received filgrastim-mobilized peripheral blood stem cell transplantation

Sponsors & Collaborators

• Amgen

  collaborator INDUSTRY

• Hoffmann-La Roche

  collaborator INDUSTRY

• European Society for Blood and Marrow Transplantation

  lead NETWORK

Principal Investigators

• Nobert Schmitz, Prof. · Christian-Albrechts- Universita¨t, Kiel, Germany

• H Greinix, Dr · Allgemeines Krankenhaus, Vienna, Austria

• D Niederwieser, Dr · University Hospital Innsbruck, Austria

• M. Boogaerts, Dr. · University Hospital, Leuven, Belgium

• A Ferrant, Dr · Cliniques Universitaires St Luc, Brussels, Belgium

• R. Arnold, Dr. · Charite der Humboldt Universität, Berlin, Germany

• E Gluckman, Dr. · Hopital St Louis, Paris, France

• N C Gorin, Dr. · Hoˆpital St Antoine, Paris, France

• N Frickhofen, Dr · Universita¨t Ulm, Germany

• P Dreger, Dr. · Christian-Albrechts- Universita¨t, Kiel, Germany

• A Zander, Dr · Universitätsklinikum Eppendorf, Hamburg, Germany

• S McCann, Dr. · St James Hospital, Dublin, Ireland

• A Nagler, Dr. · Hadassah University Hospital, Jerusalem, Israel

• A Bacigalupo, Dr. · Ospedale San Martino, Genova, Italy

• A Gratwohl, Dr. · Kantonsspital, Basel, Switzerland

• J Apperley, Prof. · Hammersmith Hospital, London, United Kingdom

• N H Russell, Dr. · Nottingham City Hospital, United Kingdom

• O Ringde´n, Dr. · Huddinge Hospital, Sweden

• I Majolino, Dr. · Ospedale V Cervello-USL, Palermo, Italy

• J P Jouet, Dr. · Hopital Claude Huriez, Lille, France

• B Varet, Dr. · Hopital Necker, Paris, France

• J Finke, Dr. · Klinikum der Albert-Ludwigs-Universität, Freiburg, Germany

• G. Smith, Dr. · Leeds General Infirmary, United Kingdom

• A Bosi, Dr. · Azienda Ospedaliera Careggi, Firenze, Italy

• G Lambertenghi-Deliliers, Dr. · Padiglione G Marcora, Ospedale Maggiore di Milano, Italy

• K Kolbe, Dr. · Universitatsklinikum, Mainz, Germany

• T Ruutu, Dr. · Helsinki University CT. Rentral Hospital, Finland

• K A Bradstock), Dr. · Westmead Hospital, Australia

• B Lioure, Dr. · LCHRU de Hautepierre, Strasbourg, France

• T Hughes, Dr. · Hanson Centre for Cancer Research, Royal Adelaide Hospital, Australia

• J Szer, Dr. · Royal Melbourne Hospital, Parkville, Australia

• R Herrmann, Dr. · Royal Perth Hospital, Australia

• L Tru¨mper, Dr. · Universitätsklinik, Homburg, Germany

• M Falda, Dr. · Centro Dipartimentale Trapianti di Midollo, Ospedale Molinette, Torino, Italy

• M Beksac, Dr. · Ankara University Medical Facility, Turkey

• E Nikiforakis, Dr. · Evangelismos General Hospital, Athens, Greece

• M Abecasis, Dr. · Instituto Portugues de Oncologia Francisco Gentil, Lisboa, Portugal

• J Rowe, Dr. · Rambam Medical Center, Haifa, Israel

• M Potter, Dr. · Royal Free Hospital Hampstead, London, United Kingdom

• H Wandt, Dr. · Medizinische Klinik Nurnberg, Germany

• R Schwerdtfeger, Dr. · Stiftung Deutsche Klinik f. Diagnostik, Wiesbaden, Germany

• J Casper, Dr · University Rostock, Germany

• A. Pagliuca, Dr. · King's College Hospital, London, United Kingdom

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1995-01-31

Primary Completion

1999-12-31

Completion

2002-12-31

Countries

• Germany

Study Locations